Checkmate raises $85M series C to support new indications for TLR9 agonist

Checkmate raised $85 million in a series C round to advance lead program CMP-001 across a range of cancer indications.

Longitude Capital and Novo Holdings A/S led the round for Cambridge, Mass.-based Checkmate Pharmaceuticals Inc., joined by fellow new investors Medicxi Ventures, Omega Funds, Clough Capital Partners, Sectoral Asset Management and BrightEdge, the venture capital fund of the American Cancer Society, as well as existing investors Sofinnova Investments, venBio Partners, F-Prime Capital Partners, and Decheng Capital...